Clinical Trial

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 3 changes
minor Completion pushed: 2027-04-10 -> 2032-12-31 2026-07-31
notable Enrollment reduced: 35 -> 31 participants 2026-04-16
minor Completion moved earlier: 2032-12-31 -> 2027-04-10 2026-04-16
Trial Details
NCT Number NCT04195399
Lead Sponsor Children's Oncology Group
Collaborators: National Cancer Institute (NCI), SpringWorks Therapeutics, Inc.
Conditions Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Enrollment 31 participants
Start Date 2020-10-07
Primary Completion 2026-03-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30